What Strepsils (Flurbiprofen) Treats: Main Uses and Benefits

The primary role of this medicine is to provide supportive relief for acute or episodic symptoms of sore throats. It is applied across domains where additional symptomatic support is needed to address increased discomfort. This includes symptomatic management of acute sore throat, pharyngitis, and discomfort associated with upper respiratory tract infections (URTIs). The medicine is relevant in settings marked by heightened symptom intensity and is commonly used as a symptomatic measure alongside antibiotics for confirmed bacterial pharyngitis, and for easing discomfort in the early stages of postoperative sore throat (POST).

The medication helps address a specific cluster of symptoms: throat pain, the feeling of a swollen throat, and difficulty swallowing (dysphagia). It is applied when these symptoms create noticeable interference with daily stability.

“The medication is commonly used to help with groups of symptoms that may appear suddenly or intensify over time, providing support that helps ease the overall symptom burden.”

---

Quick Fact: Relief for Acute Functional Strain

The supportive action can assist in maintaining functional stability, supports general well-being during symptomatic phases.

Regulatory References

1. Health Products Regulatory Authority (HPRA)

Strepsils Intensive (Flurbiprofen 8.75 mg) lozenges are generally indicated for the short-term relief of sore throat symptoms in adults and adolescents over 12 years of age. They should not be used for more than three days without consulting a healthcare professional.

---

Who Should NOT Use Strepsils (Flurbiprofen)?

Due to the active ingredient flurbiprofen, a non-steroidal anti-inflammatory drug (NSAID), this medication is contraindicated for certain individuals. You should not use Strepsils Intensive if you:

• Are under 12 years of age.
• Have an allergy to flurbiprofen, aspirin, or other NSAIDs.
• Have an active or history of recurrent peptic ulceration or gastrointestinal bleeding (two or more distinct episodes).
• Have had gastrointestinal bleeding or perforation related to previous NSAID use.
• Have severe heart, kidney, or liver failure.
• Are in the last three months of pregnancy.
• Are taking other NSAIDs (including COX-2 inhibitors) or high-dose aspirin.

Use with Caution

Consult a doctor or pharmacist before use if you are elderly, in the first or second trimester of pregnancy, are breastfeeding, or have pre-existing conditions such as asthma, high blood pressure, heart problems, systemic lupus erythematosus (SLE), or a history of inflammatory bowel diseases (e.g., Crohn's disease, ulcerative colitis).

Interactions with other medicines and products

Flurbiprofen is an NSAID, and its interaction profile reflects the systemic risks of that drug class, even in the lozenge form. Regulatory documents specify restrictions across pharmacokinetic and pharmacodynamic domains.

---

Contraindicated Combinations and Restrictions

Co-administration with other NSAIDs (including COX-2 inhibitors) and high-dose acetylsalicylic acid (>75 mg/day) is restricted due to a documented increased risk of gastrointestinal adverse effects. A mandatory administrative timing restriction applies to mifepristone: Flurbiprofen must not be used for 8 to 12 days following its administration. Co-administration with methotrexate requires separation to avoid use within 24 hours of dosing.

---

Drug-Drug Interaction Outcomes

Flurbiprofen may enhance the effects of anticoagulants, increasing the risk of bleeding. Co-administration with corticosteroids, anti-platelet agents, SSRIs, and SNRIs is noted to increase the risk of gastrointestinal bleeding or ulceration. Flurbiprofen may reduce the efficacy of antihypertensive drugs (including diuretics and ACE inhibitors) and can lead to increased serum levels of drugs like lithium and cardiac glycosides by reducing their renal clearance.

---

Metabolic and Population Considerations

The drug’s clearance via the CYP2C9 pathway is a documented interaction basis, leading to specific warnings for known poor CYP2C9 metabolizers to prevent high plasma exposure. The risk of acute renal failure is heightened when Flurbiprofen is combined with antihypertensives in populations with compromised renal function. Co-administration with alcohol may increase the risk of adverse reactions, particularly gastrointestinal bleeding.

Molecular Targets: Inhibition of Prostaglandin Synthesis

Flurbiprofen is a Non-Selective Cyclooxygenase ( COX) Inhibitor, acting on both COX1 and COX2 enzymes. By reversibly binding to these molecular targets, the drug competitively blocks the conversion of Arachidonic Acid into chemical messengers. This interaction modifies early molecular steps within the Eicosanoid Synthesis Pathway, which influences biochemical signaling related to the inflammatory response.

Localized Modulation of Mediators

The primary mechanistic consequence is the suppression of Prostaglandin E2 ( PGE2) concentration in the oropharyngeal mucosa. This reduction in mediator activity leads to a corresponding decrease in vasodilation and vascular permeability, resulting in suppressed fluid extravasation (edema), and modulates peripheral nociceptive signaling by reducing the chemical sensitization of local nerve endings. This mechanism facilitates a concentrated, localized physiological effect due to the targeted delivery, leading to modulation within the pharyngeal pathways.

How to Use Strepsils (Flurbiprofen) — Official Administration Guidelines

This information defines the procedure for using the medicine. It does not include information on safety, therapeutic uses, or side effects.

---

Administration Scope

Feature	Official Instruction
Route of Administration	Oromucosal (dissolved slowly in the mouth).
Age Restriction	For use in adults and adolescents aged 12 years and over. Not for use in children under 12 years.
Maximum Treatment Duration	Do not use for more than 3 days.

Official Dosing Protocol

The usage protocol establishes a defined schedule and limit on the amount of medicine that can be administered.

Dosing Parameter	Official Instruction
Single Dose	One lozenge (8.75 mg Flurbiprofen).
Frequency	Every 3 to 6 hours as required.
24-Hour Maximum	Do not exceed a maximum of 5 lozenges in a 24-hour period.

Procedural Steps

To ensure proper local administration, specific steps must be followed.

1. Take one lozenge.
2. Suck or dissolve the lozenge slowly in the mouth.
3. The lozenge must be moved around the mouth while sucking.
4. Wait a minimum of 3 hours before taking the next lozenge, if required.
5. Do not exceed the maximum daily dose of 5 lozenges or the maximum treatment period of 3 days.

This structured instruction set dictates the method (slow oromucosal dissolution), timing (3–6 hour interval), maximum quantity (5 per day), and total duration (3 days) for the medicine's use, strictly limiting its application to short-term use in defined age groups.

Research Evidence / Overview of Studies for Strepsils (Flurbiprofen)

---

Evidence for Use in Symptomatic Relief of Sore Throat

Research into flurbiprofen lozenges has primarily focused on conditions associated with acute or disruptive episodes. The majority of the evidence was evaluated in adults and older adolescents experiencing conditions involving periods of heightened symptoms (acute pharyngitis). Researchers examined patient-reported outcomes describing perceived discomfort, specifically outcomes related to physical discomfort and difficulty swallowing.

Findings indicate patterns observed in the studies over the brief period of a sore throat episode. Research provides insight into short-term changes measured during the study period in outcomes linked to inflammatory or irritative states. Studies report how symptoms were measured in the observed populations; many were evaluated in comparison against a placebo lozenge (an inactive treatment). It is important to remember that these findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Comparison of Flurbiprofen Studies to Placebo and Other Treatments

Studies conducted during periods of increased symptom activity often included a comparison group receiving an inactive (placebo) lozenge. These research scenarios were studied for patterns related to differences in the patient-reported outcomes describing perceived discomfort between the active group and the control group. Outcomes monitored included the measured time until participants noted a change in their symptoms.

Other research examined flurbiprofen alongside other active components which were observed in studies exploring outcomes related to systemic or functional imbalance for sore throats. The results apply only to the populations studied; they reflect the specific conditions under which they were conducted.

---

Long-Term Studies, Durability of Relief, and Extended Follow-up

Research explored short-term symptom changes over the course of an acute sore throat, which was observed in contexts relevant in trials assessing short-term or episodic symptom patterns. Long-term effects are not fully established because follow-up durations were limited. Evidence is limited regarding outcomes related to the stability or persistence of measured changes well beyond the initial short-term study period.

Evidence in Special Populations and Subgroups

Flurbiprofen lozenges was evaluated in adults and older adolescents. Data for certain groups—particularly children under 12—remain insufficient, and comparative evidence is lacking for these younger populations. Research was studied for measured outcomes in older adults with sore throats, but sample sizes were modest in some studies.

What is Still Uncertain About Flurbiprofen Research

While research was studied for measuring symptomatic changes in acute sore throat, several areas of uncertainty remain. Evidence quality varies across studies, and there is a degree of heterogeneity (differences) in how outcomes were studied for. Specifically, long-term effects are not fully established, and there is limited information for long-term outcomes after treatment has concluded. Furthermore, research is ongoing to better understand the findings for certain subgroups, and certainty remains low for populations not well represented in the major short-term RCTs.

Common questions about Strepsils(Flurbiprofen) (FAQ)

---

Q: Does Strepsils (Flurbiprofen) help with the actual infection or just the pain?

A: This medicine is indicated for the local, short-term relief of sore throat symptoms, which includes pain and inflammation. According to regulatory documents, this product is not intended to treat an underlying bacterial or viral infection. Its primary function is to provide symptomatic relief.

Q: How quickly should I feel the pain relief after using a Strepsils (Flurbiprofen) lozenge?

A: Official clinical data summaries indicate that a measurable onset of pain relief is often reported shortly after administration. This relief is typically observed by patients starting around 12 to 26 minutes after the lozenge is fully dissolved.

Q: How long does the pain-killing effect of Strepsils (Flurbiprofen) lozenges usually last?

A: The recommended dosing schedule suggests taking a lozenge every 3 to 6 hours as needed for pain. Clinical studies support that the symptomatic relief lasts for approximately 3 to 4 hours.

Q: Why do some people say Strepsils (Flurbiprofen) tastes slightly strange or numbing?

A: Official product information lists a change in taste (taste disturbance) and a tingling or numbing sensation in the mouth (oral paraesthesia) as common side effects. These local sensations are generally mild and temporary.

Q: What are the concerns about using Strepsils (Flurbiprofen) for people with high blood pressure?

A: Regulatory warnings note that Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) like flurbiprofen may cause fluid retention and swelling. This fluid retention can potentially worsen existing high blood pressure or reduce the effectiveness of blood pressure medications. This is why the product labeling advises caution for individuals with this condition.

Q: Is Strepsils (Flurbiprofen) safe for people who have asthma?

A: Official information states that individuals who have previously shown hypersensitivity reactions, such as asthma attacks or bronchospasm, after taking aspirin or other NSAIDs are advised not to use this medication. This product carries a caution for individuals with a history of asthma or allergic disease.

Q: Is Strepsils (Flurbiprofen) supposed to be used for a persistent cough or just a sore throat?

A: The medicine is specifically indicated for the local, short-term relief of sore throat symptoms. It is not listed in regulatory documents as a treatment for cough, whether persistent or acute.

Q: What happens if you accidentally swallow a Strepsils (Flurbiprofen) lozenge quickly?

A: The lozenge is formulated to be dissolved slowly in the mouth to achieve maximum localized relief. Swallowing it quickly would result in less targeted relief in the throat and slightly more rapid absorption into the body. However, symptoms of overdose are typically associated with taking an excessive amount, not accidentally swallowing a single lozenge.

Q: Can Strepsils (Flurbiprofen) be used for tonsillitis pain relief?

A: The official indication for the medicine is the symptomatic relief of acute sore throat. Tonsillitis is a common cause of severe sore throat, and the medicine can address the pain. If symptoms of tonsillitis are severe, persistent, or worsening, consulting a healthcare professional may be necessary.

Q: Can taking too many Strepsils (Flurbiprofen) lozenges cause issues?

A: Yes, exceeding the recommended maximum daily dose may lead to signs of an overdose. Regulatory warnings caution that an overdose can potentially result in symptoms such as dizziness, nausea, vomiting, and, in severe cases, gastrointestinal bleeding. This is why the lozenge has an officially recommended maximum daily dose.

Q: Does Strepsils (Flurbiprofen) make you drowsy or affect driving?

A: While generally not associated with high systemic exposure, rare side effects, such as headache or dizziness, have been reported with NSAID use. Official labeling advises that these effects may potentially affect the ability to drive or operate machinery, and users should be mindful of these effects.

Q: Is the effect of Strepsils (Flurbiprofen) purely local, or does it become systemic?

A: The lozenge is designed for oromucosal delivery to achieve a targeted local effect in the throat. While the exposure is minimized compared to taking an oral tablet, regulatory pharmacokinetic studies confirm that a small amount of the active ingredient is absorbed into the bloodstream (systemic exposure).

Q: Is it common for Strepsils (Flurbiprofen) to cause a temporary hoarseness?

A: Official regulatory safety data lists common and uncommon adverse effects, but hoarseness is not among the reported side effects in the official product information.

Q: Are there different strengths of Strepsils (Flurbiprofen) lozenges available?

A: The standard dose available in lozenge form for the relief of sore throat is 8.75 mg of flurbiprofen. Other strengths are typically associated with different, systemic formulations of flurbiprofen, used for other medical indications.

Q: Does Strepsils (Flurbiprofen) contain sugar, and is there a sugar-free version?

A: Official product information, which details the list of excipients, indicates that formulations containing sugar alcohols (e.g., isomaltitol and maltitol) as sweeteners are available. These are typically the sugar-free versions of the lozenge.

Q: Are there any long-term health concerns associated with using Strepsils (Flurbiprofen) frequently?

A: The product information specifies that the medicine is indicated for short-term use, typically a maximum of 3 days. Prolonged or frequent use of any NSAID, including flurbiprofen, is generally associated with an increased risk of serious adverse effects, particularly those affecting the gastrointestinal tract and cardiovascular system.

Q: Does Strepsils (Flurbiprofen) contain any ingredients that could trigger an allergic reaction other than the active one?

A: Yes, official documentation lists all excipients (inactive ingredients), which may include colorants, flavorings, or sweeteners. These components are listed for consumer awareness, particularly for those with known allergies, as some may cause reactions in sensitive individuals.

Q: Are there different application methods, like sprays, available for Flurbiprofen?

A: Flurbiprofen for the local relief of sore throat symptoms is available in more than one pharmaceutical form. Regulatory bodies approve its use as both a lozenge and as a throat spray solution for oromucosal administration.

Q: Is Strepsils (Flurbiprofen) considered habit-forming?

A: Flurbiprofen is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID) and is not known to be associated with abuse potential or habit formation, according to official regulatory reviews.

Q: Does Strepsils (Flurbiprofen) have any effect on fever associated with a sore throat?

A: Flurbiprofen belongs to the NSAID class of drugs, which inherently possess fever-reducing (antipyretic) properties. However, the lozenge is specifically indicated only for the symptomatic relief of sore throat and local inflammation.

Q: Why is the relief from Strepsils (Flurbiprofen) described as being anti-inflammatory?

A: The relief is described as anti-inflammatory because flurbiprofen functions by inhibiting the body's production of prostaglandins. These substances are key chemical messengers that mediate (or cause) pain and inflammation, including the swelling often felt during a sore throat.

Q: What kind of throat pain is Strepsils (Flurbiprofen) most effective for?

A: The product is officially indicated for the short-term symptomatic relief of acute sore throat. This includes the pain, swelling, and associated difficulty swallowing (dysphagia) that are characteristic of intense, rapid-onset throat discomfort.

Q: Are there specific food or drink interactions to watch out for with Strepsils (Flurbiprofen)?

A: Official product information advises that alcohol may increase the risk of gastrointestinal adverse reactions when combined with the medicine. No other specific food or non-alcoholic drink interactions are noted in regulatory documents.

How to Store and Dispose of Strepsils (Flurbiprofen) Lozenges

Official regulatory guidelines for Strepsils (Flurbiprofen) lozenges define specific conditions for storage, handling, and disposal.

Storage and Handling Requirements

Requirement	Instructions
Temperature Control	Do not store above mathbf25^circC. Do not refrigerate or freeze.
Protection	Keep in the original package (blister and carton) to protect from light and moisture.
Child Safety	Must be stored out of the sight and reach of children.

Disposal Instructions

Expired or unused Strepsils must be disposed of according to local pharmaceutical waste requirements. Regulatory guidance specifies that this medicine should not be disposed of via wastewater or routine household trash to protect the environment.